NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Shamliyan TA, Kane RL, Ramakrishnan R, et al. Migraine in Children: Preventive Pharmacologic Treatments [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Jun. (Comparative Effectiveness Reviews, No. 108.)
This publication is provided for historical reference only and the information may be out of date.
- 1.
- Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007 Mar;47(3):355–63. [PubMed: 17371352]
- 2.
- Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002 Mar 26;58(6):885–94. [PubMed: 11914403]
- 3.
- Bigal ME, Lipton RB, Winner P, et al. Migraine in adolescents: association with socioeconomic status and family history. Neurology. 2007 Jul 3;69(1):16–25. [PubMed: 17606878]
- 4.
- Hernandez-Latorre MA, Roig M. Natural history of migraine in childhood. Cephalalgia. 2000 Jul;20(6):573–9. [PubMed: 11075841]
- 5.
- Lewis DW. Pediatric migraine. Neurol Clin. 2009 May;27(2):481–501. [PubMed: 19289227]
- 6.
- Goadsby PJ, Raskin NH. Chapter 15 Headache. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., editors. Harrison's principles of internal medicine. 17th ed. New York: The McGraw-Hill Co mpanies; 2008.
- 7.
- Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9–160. [PubMed: 14979299]
- 8.
- Silberstein SD. Preventive migraine treatment. Neurol Clin. 2009 May;27(2):429–43. [PubMed: 19289224]
- 9.
- Lipton RB, Manack A, Ricci JA, et al. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache. 2011 May;51(5):693–706. [PubMed: 21521206]
- 10.
- Bille B. A 40-year follow-up of school children with migraine. Cephalalgia. 1997 Jun;7(4):488–91. discussion 7. [PubMed: 9209767]
- 11.
- Guidetti V, Galli F. Evolution of headache in childhood and adolescence: an 8-year follow-up. Cephalalgia. 1998 Sep;18(7):449–54. [PubMed: 9793696]
- 12.
- Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001 Jul-Aug;41(7):646–57. [PubMed: 11554952]
- 13.
- Damen L, Bruijn JK, Verhagen AP, et al. Symptomatic treatment of migraine in children: a systematic review of medication trials. Pediatrics. 2005 Aug;116(2):e295–302. [PubMed: 16061583]
- 14.
- Sprenger T, Goadsby PJ. Migraine pathogenesis and state of pharmacological treatment options. BMC Medicine. 2009;7:71. [PMC free article: PMC2784479] [PubMed: 19917094]
- 15.
- Sanchez-Del-Rio M, Reuter U, Moskowitz MA. New insights into migraine pathophysiology. Curr Opin Neurol. 2006 Jun;19(3):294–8. [PubMed: 16702838]
- 16.
- Rapoport AM. Acute and prophylactic treatments for migraine: present and future. Neurol Sci. 2008 May;29 Suppl 1:S110–22. [PubMed: 18545911]
- 17.
- Stafford RS. Regulating off-label drug use--rethinking the role of the FDA. N Engl J Med. 2008 Apr 3;358(14):1427–9. [PubMed: 18385495]
- 18.
- Fraguas D, Merchan-Naranjo J, Laita P, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. Journal of Clinical Psychiatry. 2008 Jul;69(7):1166–75. [PubMed: 18588363]
- 19.
- Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006 Jul;45(7):771–91. [PubMed: 16832314]
- 20.
- Pappagallo M, Silva R. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol. 2004 Fall;14(3):359–71. [PubMed: 15650493]
- 21.
- Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008 Jan;34(1):60–71. [PMC free article: PMC2632383] [PubMed: 17923452]
- 22.
- Dubois D. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Curr Opin Pediatr. 2005 Apr;17(2):227–33. [PubMed: 15800418]
- 23.
- Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008 May;28(5):484–95. [PubMed: 18294250]
- 24.
- Schroeder BM. AAFP/ACP-ASIM release guidelines on the management and prevention of migraines. Am Fam Physician. 2003 Mar 15;671392(6):5–7. [PubMed: 12674472]
- 25.
- Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006 Jun;26(6):742–6. [PubMed: 16686915]
- 26.
- Lewis D, Ashwal S, Hershey A, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004 Dec 28;63(12):2215–24. [PubMed: 15623677]
- 27.
- Gunner KB, Smith HD, Ferguson LE. Practice guideline for diagnosis and management of migraine headaches in children and adolescents: Part two. J Pediatr Health Care. 2008 Jan-Feb;22(1):52–9. [PubMed: 18174091]
- 28.
- Geraud G, Lanteri-Minet M, Lucas C, et al. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther. 2004 Aug;26(8):1305–18. [PubMed: 15476911]
- 29.
- Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009 Sep;16(9):968–81. [PubMed: 19708964]
- 30.
- Dowson AJ, Lipscombe S, Sender J, et al. New guidelines for the management of migraine in primary care. Curr Med Res Opin. 2002;18(7):414–39. [PubMed: 12487508]
- 31.
- Morey SS. Guidelines on migraine: part 4. General principles of preventive therapy. Am Fam Physician. 2000 Nov 15;62(10):2359–60. 2000. [PubMed: 11126860]
- 32.
- Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 Sep 26;55(6):754–62. [PubMed: 10993991]
- 33.
- Schuurmans A, van Weel C. Pharmacologic treatment of migraine. Comparison of guidelines. Can Fam Physician. 2005 Jun;51:838–43. [PMC free article: PMC1479536] [PubMed: 15986940]
- 34.
- Solomon S. New appendix criteria open for a broader concept of chronic migraine (Comment on: Cephalagia 2006 Jun:26(6):742-6). Cephalalgia. 2007 May;27(5):469. author reply -70. [PubMed: 17448186]
- 35.
- U.S. Food and Drug Administration. FDA News Release: FDA Approves Botox to Treat Chronic Migraine. 2010. [July 25 2012]. http://www
.fda.gov/NewsEvents /Newsroom/PressAnnouncements /ucm229782.htm. - 36.
- Whitlock EP, Lopez SA, Chang S, et al. AHRQ series paper 3: identifying, selecting, and refining topics for comparative effectiveness systematic reviews: AHRQ and the effective health-care program. J Clin Epidemiol. 2010 May;63(5):491–501. [PubMed: 19540721]
- 37.
- Slutsky J, Atkins D, Chang S, et al. AHRQ series paper 1: comparing medical interventions: AHRQ and the Effective Health-Care Program. J Clin Epidemiol. 2010 May;63(5):481–3. [PubMed: 18834715]
- 38.
- Helfand M, Balshem H. AHRQ series paper 2: principles for developing guidance: AHRQ and the Effective Health-Care Program. J Clin Epidemiol. 2010 May;63(5):484–90. [PubMed: 19716268]
- 39.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine. 2009 Aug 18;151(4):W65–94. [PubMed: 19622512]
- 40.
- White CM, Ip S, McPheeters ML, et al. Chapter 11. Using existing systematic reviews to replace de novo processes in conducting comparative effectiveness reviews. Methods Guide for Effectiveness and Comparative Reviews. Rockville, MD: Agency for Healthcare Resarch and Quality; Mar, 2011. pp. 136–51. AHRQ Publication No. 10(11)-EHC063-EF. 2009. Available at www
.effectivehealthcare.ahrq.gov. [PubMed: 21433402] - 41.
- Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001 Apr;20(3 Suppl):21–35. [PubMed: 11306229]
- 42.
- Rothner AD. Complicated migraine and migraine variants. Curr Pain Headache Rep. 2002 Jun;6(3):233–9. [PubMed: 12003695]
- 43.
- Hansen JM, Thomsen LL, Olesen J, et al. Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. Neurology. 2008 Sep 9;71(11):841–7. [PubMed: 18779512]
- 44.
- Norris S, Atkins D, Bruening W, et al. Chapter 4. Selecting observational studies for comparing medical interventions. Methods Guide for Effectiveness and Comparative Reviews. Rockville, MD: Agency for Healthcare Research and Quality; Mar, 2011. pp. 56–68. AHRQ Publication No. 10(11)-EHC063-EF. Available at: www
.effectivehealthcare.ahrq.gov. - 45.
- Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions. London: The Cochrane Collaboration; 2011. Version 5.1.0.
- 46.
- Chou R, Aronson N, Atkins D, et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the Effective Health-Care Program. J Clin Epidemiol. 2008 Sep 25;63(5):502–12. [PubMed: 18823754]
- 47.
- Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. [PMC free article: PMC3196245] [PubMed: 22008217]
- 48.
- Viswanathan M, Berkman ND. Development of the RTI Item Bank on Risk of Bias and Precision of Observational Studies AHRQ Methods for Effective Health Care. Rockville (MD): Agency for Healthcare Research and Quality (US); Sep, 2011. Studies. (Report No.: 11-EHC028-EF) [PubMed: 22191112]
- 49.
- van der Velde G, van Tulder M, Cote P, et al. The sensitivity of review results to methods used to appraise and incorporate trial quality into data synthesis. Spine (Phila Pa 1976). 2007 Apr 1;32(7):796–806. [PubMed: 17414916]
- 50.
- Herbison P, Hay-Smith J, Gillespie WJ. Adjustment of meta-analyses on the basis of quality scores should be abandoned. J Clin Epidemiol. 2006 Dec;59(12):1249–56. [PubMed: 17098567]
- 51.
- Wallace BC, Schmid CH, Lau J, et al. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol. 2009;9:80. [PMC free article: PMC2795760] [PubMed: 19961608]
- 52.
- Egger M, Smith GD, Altman DG. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ Books; 2001.
- 53.
- Fu R, Gartlehner G, Grant M, et al. Chapter 9. Conducting quantitative synthesis when comparing medical interventions. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; Mar, 2011. pp. 104–19. AHRQ Publication No. 10(11)-EHC063-EF. Available at: http:
//effectivehealthcare.ahrq.gov. - 54.
- Rucker G, Schwarzer G, Carpenter J, et al. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. Stat Med. 2009 Feb 28;28(5):721–38. [PubMed: 19072749]
- 55.
- Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007 Jan 15;26(1):53–77. [PubMed: 16596572]
- 56.
- Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004 May 15;23(9):1351–75. [PubMed: 15116347]
- 57.
- Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010 Dec 20;29(29):3046–67. [PubMed: 20827667]
- 58.
- Friedrich JO, Adhikari NK, Beyene J. Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods. Journal of Clinical Epidemiology. 2011 May;64(5):556–64. [PubMed: 21447428]
- 59.
- Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the Effective Health-Care Program. J Clin Epidemiol. 2010 May;63(5):513–23. [PubMed: 19595577]
- 60.
- Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med. 2007 Jan 15;26(1):37–52. [PubMed: 16463355]
- 61.
- Knapp G, Biggerstaff BJ, Hartung J. Assessing the amount of heterogeneity in random-effects meta-analysis. Biom J. 2006 Apr;48(2):271–85. [PubMed: 16708778]
- 62.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–88. [PubMed: 3802833]
- 63.
- Ebrahim S. The use of numbers needed to treat derived from systematic reviews and meta-analysis. Caveats and pitfalls. Eval Health Prof. 2001 Jun;24(2):152–64. [PubMed: 11523384]
- 64.
- Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998 Nov 7;317(7168):1309–12. [PMC free article: PMC1114210] [PubMed: 9804726]
- 65.
- Guyatt G, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol. 2011 Aug 10 [PubMed: 34174652]
- 66.
- Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. [PubMed: 21784880]
- 67.
- Guyatt GH, Oxman AD, Santesso N, et al. GRADE guidelines 12. Preparing Summary of Findings tables-binary outcomes. J Clin Epidemiol. 2012 May 18 [PubMed: 22609141]
- 68.
- Aschengrau A, Seage GR. Essentials of epidemiology in public health. Sudbury, MA: Jones and Bartlett; 2003.
- 69.
- U.S. Food and Drug Administration. Clinical Review of Divalproex Sodium. 2008
- 70.
- Battistella PA, Ruffilli R, Cernetti R, et al. A placebo-controlled crossover trial using trazodone in pediatric migraine. Headache. 1993 Jan;33(1):36–9. [PubMed: 8436497]
- 71.
- Sillanpää M. Clonidine prophylaxis of childhood migraine and other vascular headache. A double blind study of 57 children. Headache. 1977:28–31. [PubMed: 321395]
- 72.
- Sills M, Congdon P, Forsythe I. Clonidine and childhood migraine: a pilot and double-blind study. Dev Med Child Neurol. 1982 Dec;24(6):837–41. [PubMed: 6218003]
- 73.
- Apostol G, Cady RK, Laforet GA, et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache. 2008 Jul;48(7):1012–25. [PubMed: 18705027]
- 74.
- Wang F, Van Den Eeden SK, Ackerson LM, et al. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache. 2003 Jun;43(6):601–10. [PubMed: 12786918]
- 75.
- Sartory G, Muller B, Metsch J, et al. A comparison of psychological and pharmacological treatment of pediatric migraine. Behav Res Ther. 1998 Dec;36(12):1155–70. [PubMed: 9745800]
- 76.
- Battistella PA, Ruffilli R, Moro R, et al. A placebo-controlled crossover trial of nimodipine in pediatric migraine. Headache. 1990 Apr;30(5):264–8. [PubMed: 2191938]
- 77.
- Olness K, MacDonald JT, Uden DL. Comparison of self-hypnosis and propranolol in the treatment of juvenile classic migraine. Pediatrics. 1987 Apr;79(4):593–7. [PubMed: 3822681]
- 78.
- Bidabadi E, Mashouf M. A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients. Paediatric Drugs. 2010 Aug 1;12(4):269–75. [PubMed: 20593910]
- 79.
- Ludvigsson J. Propranolol used in prophylaxis of migraine in children. Acta neurologica Scandinavica. 1974:109–15. [PubMed: 4839065]
- 80.
- Forsythe WI, Gillies D, Sills MA. Propanolol ('Inderal') in the treatment of childhood migraine. Developmental medicine and child neurology. 1984:737–41. [PubMed: 6519358]
- 81.
- Winner P, Pearlman EM, Linder SL, et al. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache. 2005 Nov-Dec;45(10):1304–12. [PubMed: 16324162]
- 82.
- Winner P, Gendolla A, Stayer C, et al. Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety. Headache. 2006 Nov-Dec;46(10):1503–10. [PubMed: 17115983]
- 83.
- Lakshmi CV, Singhi P, Malhi P, et al. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. J Child Neurol. 2007 Jul;22(7):829–35. [PubMed: 17715274]
- 84.
- Lewis D, Paradiso E. A double-blind, dose comparison study of topiramate for prophylaxis of basilar-type migraine in children: a pilot study. Headache. 2007 Nov-Dec;47(10):1409–17. [PubMed: 18052950]
- 85.
- Unalp A, Uran N, Ozturk A. Comparison of the effectiveness of topiramate and sodium valproate in pediatric migraine. J Child Neurol. 2008 Dec;23(12):1377–81. [PubMed: 19073842]
- 86.
- Lewis D, Winner P, Saper J, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics. 2009 Mar;123(3):924–34. [PubMed: 19255022]
- 87.
- Pandina GJ, Ness S, Polverejan E, et al. Cognitive effects of topiramate in migraine patients aged 12 through 17 years. Pediatr Neurol. 2010 Mar;42(3):187–95. [PubMed: 20159428]
- 88.
- Ashrafi MR, Shabanian R, Zamani GR, et al. Sodium Valproate versus Propranolol in paediatric migraine prophylaxis. Eur J Paediatr Neurol. 2005;9(5):333–8. [PubMed: 16120482]
- 89.
- Trautmann E, Kroner-Herwig B. A randomized controlled trial of Internet-based self-help training for recurrent headache in childhood and adolescence. Behav Res Ther. 2010 Jan;48(1):28–37. [PubMed: 19782343]
- 90.
- Cruz MJ, Valencia I, Legido A, et al. Efficacy and tolerability of topiramate in pediatric migraine. Pediatric Neurology. 2009 Sep;41(3):167–70. [PubMed: 19664530]
- 91.
- Jurgens TP, Ihle K, Stork JH, et al. “Alice in Wonderland syndrome” associated with topiramate for migraine prevention. J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):228–9. [PubMed: 20571045]
- 92.
- Apostol G, Lewis DW, Laforet GA, et al. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. Headache. 2009 Jan;49(1):45–53. [PubMed: 19040679]
- 93.
- Pakalnis A, Greenberg G, Drake ME Jr, et al. Pediatric migraine prophylaxis with divalproex. Journal of Child Neurology. 2001 Oct;16(10):731–4. [PubMed: 11669346]
- 94.
- Sorge F, Barone P, Steardo L. Amitriptyline as a prophylactic for migraine in children. Acta Neurologica. 1982;4(5):362–7. [PubMed: 7158453]
- 95.
- Chan VW, McCabe EJ, MacGregor DL. Botox treatment for migraine and chronic daily headache in adolescents. Journal of Neuroscience Nursing. 2009 Oct;41(5):235–43. [PubMed: 19835236]
- 96.
- Apostol G, Pakalnis A, Laforet GA, et al. Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents. Headache. 2009 Jan;49(1):36–44. [PubMed: 19040678]
- 97.
- Sorge F, De Simone R, Marano E, et al. Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study. Cephalalgia. 1988:1–6. [PubMed: 3282670]
- 98.
- Victor S, Ryan SW. Drugs for preventing migraine headaches in children. Cochrane Database of Systematic Reviews. 2003;(4):CD002761. [PubMed: 14583952]
- 99.
- Damen L, Bruijn J, Koes BW, et al. Prophylactic treatment of migraine in children. Part 1. A systematic review of non-pharmacological trials. Cephalalgia. 2006 Apr;26(4):373–83. [PubMed: 16556238]
- 100.
- Larsson B, Carlsson J, Fichtel A, et al. Relaxation treatment of adolescent headache sufferers: results from a school-based replication series. Headache. 2005 Jun;45(6):692–704. [PubMed: 15953302]
- 101.
- Fichtel A, Larsson B. Relaxation treatment administered by school nurses to adolescents with recurrent headaches. Headache. 2004 Jun;44(6):545–54. [PubMed: 15186298]
- 102.
- Jayapal S, Maheshwari N. Question 3. Topiramate for chronic migraine in children. Arch Dis Child. 2011 Mar;96(3):318–21. [PubMed: 21317129]
- 103.
- Damen L, Bruijn J, Verhagen AP, et al. Prophylactic treatment of migraine in children. Part 2. A systematic review of pharmacological trials. Cephalalgia. 2006 May;26(5):497–505. [PubMed: 16674757]
- 104.
- Connock M, Frew E, Evans BW, et al. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review. Health Technol Assess. 2006 Mar;10(7):iii–ix-118. [PubMed: 16545206]
- 105.
- Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007 Apr 18;297(15):1683–96. [PubMed: 17440145]
- 106.
- Breslau N. Psychiatric comorbidity in migraine. Cephalalgia. 1998 Aug;18 Suppl 22:56–8. discussion 8-61. [PubMed: 9793713]
- 107.
- Tfelt-Hansen P, Bjarnason NH, Dahl, et al. Evaluation and registration of adverse events in clinical drug trials in migraine. Cephalalgia. 2008 Jul;28(7):683–8. [PubMed: 18498392]
- 108.
- Wasiewski WW. Preventive therapy in pediatric migraine. Journal of Child Neurology. 2001 Feb;16(2):71–8. [PubMed: 11292228]
- 109.
- Sorge F, Marano E. Flunarizine v. placebo in childhood migraine. A double-blind study. Cephalalgia. 1985 May;5 Suppl 2:145–8. [PubMed: 2861907]
- 110.
- Sinha IP, Altman DG, Beresford MW, et al. Standard 5: Selection, Measurement, and Reporting of Outcomes in Clinical Trials in Children. Pediatrics. 2012 June 1;129(Supplement 3):S146–S52. 2012. [PubMed: 22661761]
- 111.
- van der Tweel I, Askie L, Vandermeer B, et al. Standard 4: Determining Adequate Sample Sizes. Pediatrics. 2012 June 1;129(Supplement 3):S138–S45. 2012. [PubMed: 22661760]
- 112.
- Ellenberg S, Fernandes RM, Saloojee H, et al. Standard 3: Data Monitoring Committees. Pediatrics. 2012 June 1;129(Supplement 3):S132–S7. 2012. [PubMed: 22661759]
- 113.
- Hartling L, Hamm M, Klassen T, et al. Standard 2: Containing Risk of Bias. Pediatrics. 2012 June 1;129(Supplement 3):S124–S31. 2012. [PubMed: 22661758]
- 114.
- Caldwell PHY, Dans L, de Vries MC, et al. Standard 1: Consent and Recruitment. Pediatrics. 2012 June 1;129(Supplement 3):S118–S23. 2012. [PubMed: 22661757]
- 115.
- Hartling L, Wittmeier KDM, Caldwell P, et al. StaR Child Health: Developing Evidence-Based Guidance for the Design, Conduct, and Reporting of Pediatric Trials. Pediatrics. 2012 June 1;129(Supplement 3):S112–S7. 2012. [PubMed: 22661756]
- 116.
- van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, et al. Antiepileptic drug utilization in children from 1997-2005--a study from the Netherlands. Eur J Clin Pharmacol. 2008 Oct;64(10):1013–20. [PubMed: 18618103]
- 117.
- Bazzano AT, Mangione-Smith R, Schonlau M, et al. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr. 2009 Mar-Apr;9(2):81–8. [PubMed: 19329098]
- 118.
- Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Safety. 2002;25(1):1–5. [PubMed: 11820908]
- 119.
- Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002 Dec;54(6):665–70. [PMC free article: PMC1874497] [PubMed: 12492616]
- 120.
- Ufer M, Kimland E, Bergman U. Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Saf. 2004 Mar;13(3):147–52. [PubMed: 15072113]
- 121.
- Shamliyan T, Kane RL. Clinical research involving children: registration, completeness, and publication. Pediatrics. 2012 May;129(5):e1291–300. [PubMed: 22529271]
- References - Migraine in Children: Preventive Pharmacologic TreatmentsReferences - Migraine in Children: Preventive Pharmacologic Treatments
Your browsing activity is empty.
Activity recording is turned off.
See more...